Case Report: Renal relapse after heart transplantation, induction, and autologous stem cell transplantation in a patient with AL amyloidosis with exclusive cardiac involvement
Borja Puertas, Beatriz Rey-Búa, R. Eiros, Alberto Martín-Arribas, E. Montero-Mateos, A. Hernandez-Sanchez, S. Gómez-Úbeda, Elena Alejo-Alonso, Ana A. Martín-López, P. Antunez, Eduardo Villacorta-Argüelles, M. Gallego-Delgado, N. Puig, M. Mateos, V. González-Calle
{"title":"Case Report: Renal relapse after heart transplantation, induction, and autologous stem cell transplantation in a patient with AL amyloidosis with exclusive cardiac involvement","authors":"Borja Puertas, Beatriz Rey-Búa, R. Eiros, Alberto Martín-Arribas, E. Montero-Mateos, A. Hernandez-Sanchez, S. Gómez-Úbeda, Elena Alejo-Alonso, Ana A. Martín-López, P. Antunez, Eduardo Villacorta-Argüelles, M. Gallego-Delgado, N. Puig, M. Mateos, V. González-Calle","doi":"10.3389/frhem.2022.997262","DOIUrl":null,"url":null,"abstract":"There is no recommendation on what salvage therapy is optimal in the solid organ recipient with AL amyloidosis, such as a heart transplant. With this case, we illustrate how treatment with daratumumab may be effective and safe in a patient with AL amyloidosis with renal involvement at the relapse after heart transplantation and autologous stem cell transplantation.","PeriodicalId":101407,"journal":{"name":"Frontiers in hematology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frhem.2022.997262","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
There is no recommendation on what salvage therapy is optimal in the solid organ recipient with AL amyloidosis, such as a heart transplant. With this case, we illustrate how treatment with daratumumab may be effective and safe in a patient with AL amyloidosis with renal involvement at the relapse after heart transplantation and autologous stem cell transplantation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
